Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Pierre Emmanuel Stoebner"'
Autor:
Mathilde Amiot, Laurent Mortier, Stéphane Dalle, Olivier Dereure, Sophie Dalac, Caroline Dutriaux, Marie-Thérèse Leccia, Eve Maubec, Jean-Philippe Arnault, Florence Brunet-Possenti, Julie De Quatrebarbes, Florence Granel-Brocard, Caroline Gaudy-Marqueste, Cecile Pages, Pierre-Emmanuel Stoebner, Philippe Saiag, Thierry Lesimple, Alain Dupuy, Delphine Legoupil, Henri Montaudié, Bastien Oriano, Celeste Lebbe, Raphael Porcher
Publikováno v:
EClinicalMedicine, Vol 78, Iss , Pp 102960- (2024)
Summary: Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until progression or toxicity, or f
Externí odkaz:
https://doaj.org/article/a35fcde11aaa4a9a95930be7f5508224
Autor:
Ariane Fizazi, Chris Serrand, Alexandre Evrard, Blanche Bergeret, Pierre-Emmanuel Stoebner, Myriam Marque
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
The prognostic value of BRAF V600 mutation level on clinical outcomes in patients with BRAF V600-mutated metastatic melanoma treated with BRAF and MEK inhibitors remains uncertain. The association was retrospectively analysed between BRAF V600 mutati
Externí odkaz:
https://doaj.org/article/261171b80a1944d993f8eed7e8c78592
Autor:
Marguerite Kandel, Aurélie Bardet, Stéphane Dalle, Clara Allayous, Laurent Mortier, Bernard Guillot, Caroline Dutriaux, Marie-Thérèse Leccia, Sophie Dalac, Henri Montaudie, Philippe Saiag, Delphine Legoupil, Florence Brunet-Possenti, Jean-Philippe Arnault, Julie De Quatrebarbes, Marie Beylot-Barry, Eve Maubec, Thierry Lesimple, François Aubin, Jean-Jacques Grob, Florence Granel-Brocard, Pierre-Emmanuel Stoebner, Alain Dupuy, Brigitte Dreno, Stefan Michiels, Céleste Lebbe, Isabelle Borget
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9255-9270 (2022)
Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear. To inform policy-makers about their efficiency, we performed a c
Externí odkaz:
https://doaj.org/article/029219c40f474f67aac932d94f25d323
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 3:167-180
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::610ccc6ebfcdae3a56a1ce191faf5a6b
https://doi.org/10.1016/j.fander.2023.01.002
https://doi.org/10.1016/j.fander.2023.01.002
Autor:
Manon Girod, Stéphane Dalle, Laurent Mortier, Sophie Dalac, Marie-Thèrèse Leccia, Caroline Dutriaux, Henri Montaudié, Julie de Quatrebarbes, Thierry Lesimple, Florence Brunet-Possenti, Philippe Saiag, Eve Maubec, Delphine Legoupil, Pierre-Emmanuel Stoebner, Jean Philippe Arnault, Wendy Lefevre, Celeste Lebbe, Olivier Dereure
Publikováno v:
JCO precision oncology. 6
PURPOSE Mitogen-activating protein kinase inhibitors (MAPKis) are largely used in V600E/K BRAF–mutated metastatic melanomas, but data regarding effectiveness of targeted therapy in patients with rare BRAF mutations and molecular description of thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::296c259a9e95eff6c39b540f79e35811
https://pubmed.ncbi.nlm.nih.gov/36356284
https://pubmed.ncbi.nlm.nih.gov/36356284
Publikováno v:
Dermatologic Surgery. 49:625-626
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb7bf24a8409e396fe6221efda914ca7
https://doi.org/10.1097/dss.0000000000003796
https://doi.org/10.1097/dss.0000000000003796
Autor:
Laure Cayrefourcq, Aurélie De Roeck, Caroline Garcia, Pierre-Emmanuel Stoebner, Fanny Fichel, Françoise Garima, Françoise Perriard, Jean-Pierre Daures, Laurent Meunier, Catherine Alix-Panabières
Publikováno v:
Cells, Vol 8, Iss 7, p 755 (2019)
Metastatic melanoma is one of the most aggressive and drug-resistant cancers with very poor overall survival. Circulating melanoma cells (CMCs) were first described in 1991. However, there is no general consensus on the clinical utility of CMC detect
Externí odkaz:
https://doaj.org/article/2e7ae4ceac3d4eb99b78ca0a488ccc9e
Autor:
Anne Bonhoure, Laurent Henry, Claudia Bich, Lionel Blanc, Blanche Bergeret, Marie‐Pierre Bousquet, Olivier Coux, Pierre‐Emmanuel Stoebner, Michel Vidal
Publikováno v:
Traffic (Copenhagen, Denmark)REFERENCES. 23(5)
Proteasomes are major non-lysosomal proteolytic complexes localized in the cytoplasm and in the nucleus of eukaryotic cells. Strikingly, high levels of extracellular proteasome have also been evidenced in the plasma (p-proteasome) of patients with sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1d0714fd7227df4655ae9e8737c21ed
https://pubmed.ncbi.nlm.nih.gov/35466519
https://pubmed.ncbi.nlm.nih.gov/35466519
Autor:
Léo Plaçais, Stéphane Dalle, Olivier Dereure, Sabiha Trabelsi, Sophie Dalac, Delphine Legoupil, Henri Montaudié, Jean-Philippe Arnault, Julie De Quatrebarbes, Philippe Saiag, Florence Brunet-Possenti, Thierry Lesimple, Eve Maubec, François Aubin, Florence Granel-Brocard, Jean-Jacques Grob, Pierre-Emmanuel Stoebner, Clara Allayous, Bastien Oriano, Caroline Dutriaux, Laurent Mortier, Céleste Lebbe
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 2022, 81 (10), pp.1445-1452. ⟨10.1136/ard-2022-222186⟩
Annals of the Rheumatic Diseases, 2022, 81 (10), pp.1445-1452. ⟨10.1136/ard-2022-222186⟩
ObjectiveTo quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma.MethodsCase–control study performed on a Fren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6939047d134b5d37055588258f142673
https://pubmed.ncbi.nlm.nih.gov/35788496
https://pubmed.ncbi.nlm.nih.gov/35788496
Autor:
Pierre-Emmanuel Stoebner, Christophe Bedane, A. Jannic, Marc Dumas, Marie Moncourier, Sandrine Mansard, Anne-Bénédicte Duval-Modeste, David Solub, Sophie Darras, Suzanne Devaux, Julia Sanchez, Nicolas Meyer, Laurent Misery, Valentine Heidelberger, Raoul Triller, Ingrid Kupfer-Bessaguet, Nathalie Beneton, Florence Brunet-Possenti, Gaëlle Quéreux, E. Maubec, Sophie Dalac, François Skowron, Safia Abed, Caroline Gaudy-Marqueste, Laurent Mortier, Monica Dinulescu, F. Herms, Lucie Peuvrel, Marouane Boubaya, Candice Hober, Pierre Guillet, Mahtab Samimi, Yves Reguerre, Nicolas Poulalhon, Anne Pham-Ledard, Stéphanie Catala, Eve-Marie Neidhardt, Romain Lesbazeilles, Jean-Philippe Arnault, Brigitte Dréno, Olivier Collard, Philippe Celerier, Julie De Quatrebarbes, Youssef Tazi, Pierre Combe, Caroline Jacobzone, Élodie Archier, F. Aubin, Dominique Spaeth, Clémence Berthin, Nora Kramkimel, Florent Grange, Candice Lesage, Lisa Fredeau, A. Schoeffler, Marc Pracht, Bertille Bonniaud, Laure Cesaire, Maxime Etienne, Olivier Lauche
Publikováno v:
Cancers
Cancers, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Cancers, Vol 13, Iss 3547, p 3547 (2021)
Cancers, MDPI, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Volume 13
Issue 14
Cancers, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Cancers, Vol 13, Iss 3547, p 3547 (2021)
Cancers, MDPI, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Volume 13
Issue 14
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc71b63af8c9862b6ab08fc449cfdcd5
https://hal.inrae.fr/hal-03332168
https://hal.inrae.fr/hal-03332168
